SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-038778
Filing Date
2023-03-30
Accepted
2023-03-30 08:15:13
Documents
14
Period of Report
2023-03-30
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2310776d1_8k.htm   iXBRL 8-K 27991
2 EXHIBIT 99.1 tm2310776d1_ex99-1.htm EX-99.1 26010
6 GRAPHIC tm2310776d1_ex99-1img001.jpg GRAPHIC 7336
  Complete submission text file 0001104659-23-038778.txt   247309

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA syn-20230330.xsd EX-101.SCH 3060
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE syn-20230330_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE syn-20230330_pre.xml EX-101.PRE 22614
8 EXTRACTED XBRL INSTANCE DOCUMENT tm2310776d1_8k_htm.xml XML 3614
Mailing Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850
Business Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850 (734) 332-7800
Theriva Biologics, Inc. (Filer) CIK: 0000894158 (see all company filings)

IRS No.: 133808303 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12584 | Film No.: 23777244
SIC: 2834 Pharmaceutical Preparations